CureMatch
×
  • Physicians
  • BioPharma
  • Employers
  • News
  • Clinical Order
  • About Us
  • Login

CureMatch Tsigelny Presents at PCS 4th Annual Global Cancer Conference

CureMatch Tsigelny Presents at PCS 4th Annual Global Cancer Conference
Press Releases

LISBON, PORTUGAL – CureMatch is proud to announce that CureMatch Chief Technology Officer and co-founder, Igor Tsigelny, PhD was invited in November as a plenary speaker to the PCS 4th Annual Global Cancer Conference-2017 in Lisbon, Portugal.

The international meeting focused on basic research and clinical cancer research. Presentations and discussions concerning top cancer killers and treatment options prompted partnerships and sparked new ideas for future innovative cancer treatments and standard of care.

Dr. Tsigelny was the chair of the keynote session, and presented a paper detailing CureMatch’s approach to clinical decision support in oncology. The abstract is attached below:

Title: Personalized Cancer Medicine: System for Physician Decision Support

Dr. Igor F. Tsigelny 1,2 (GCC), Boichard, A 1,2, Richard, S 1, Kurzrock, R 2

1 CureMatch Inc., USA

2 University of California, USA

Abstract

We present the new decision-support system for personalized medicine. This system is developed at CureMatch (San Diego) . It is an interactive tool helping physicians to review possible therapeutic options in cancer treatment based on genomic, proteomic, and other profiles of patients. Our system takes in consideration activities and toxicities of drugs, uses proprietary rule-based system to address gene aberrations with optimal combinations of drugs. Priority is given to combinations of drugs covering the highest number of targets and using a minimal number of drugs. Optimal combinations usually present the highest Matching Score. Combinations that include approved drugs and on-label are presented ahead of those that include approved but off-label drugs. The system allows the user to set up additional criteria, such as the use of ‘mandatory’ drugs or the eviction of ‘unwanted’ drugs. Therefore, the initial input may be modified at any time, and such updates may result in updated outputs. The system will report known drug-drug interactions as well. Our system also recommends immunotherapies. When relevant (i.e. when the molecular profile includes a marker of response for immunotherapy), immunotherapies are proposed alone or in combination with any additional drug of interest.

Note, that there are now specific response and resistance markers that have been published for immunotherapy and these can be ascertained from genomic profiling ( e.g., microsatellite instability, PD-Ll amplification, high tumor mutational burden etc.) and/or immunohistochemistry tests (PD-Ll tumor positivity).

Presenter Biography

Igor F. Tsigelny Co-founder and Chief Technology Officer at CureMatch Inc. and Professor of University of California, San Diego.

He is a leading expert in structural biology, molecular modeling, bioinformatics, and structure-based drug design. Dr. Tsigelny published more than 200 papers in scientific journals, co-authored and edited 4 scientific books. He has around 15 existing and pending patents. His computational study of molecular mechanisms of Parkinson’s disease has been included in the US Department of Energy publication “Decade of Discovery” where the best computational studies of the decade 1999-2009 have been described.

The Interests of Research and Collaboration: CureMatch, Inc., based in San Diego, is a digital health company focused on personalized medicine and combination therapy in oncology. Combination therapy has been used effectively in the treatment of other diseases, such as HIV/ AIDS, and is considered by many to be the future of cancer treatment. CureMatch’s report guides oncologists in the selection of combinations of cancer drugs that are personalized for individual patients, based on the molecular profile of the patient’s own tumor. The CureMatch technology has a foundation in supercomputing, oncology, genetics, proteomics, biochemistry, and cell biology. For more information, visit www.curematch.com.

About CureMatch

CureMatch, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. CureMatch’s Decision Support System guides oncologists in the selection of cancer drugs that are customized for individual patients based on their molecular tumor profile. CureMatch enables oncologists to become experts in personalized medicine by providing them with actionable intelligence towards advanced cancer treatment options. www.curematch.com.

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • Launch of CureMatch Certified Precision Oncology Recognition Award

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

  • The Complex Cancer Puzzle | Video 1

    ShareLinkedInFacebookTwitterRedditEmailPrint

  • CureMatch and Mprobe Partner to Help Cancer Patients Determine Optimal Treatments

    CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues....

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

Validation

  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

    Malignancies are molecularly complex and become more resistant with each line of...

  • Significance of Scores Generated by a Cancer Therapy Matching Engine for Patient Outcomes

    Oncologists need effective precision medicine tools to navigate the myriad of therapeutic...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

Archives

  • May 2024 (1)
  • October 2023 (1)
  • June 2023 (1)
  • May 2023 (1)
  • March 2023 (1)
  • January 2023 (1)
  • July 2022 (2)
  • June 2022 (2)
  • April 2022 (1)
  • March 2022 (1)
  • February 2022 (3)
  • November 2021 (1)
  • October 2021 (2)
  • August 2021 (2)
  • July 2021 (1)
  • June 2021 (4)
  • May 2021 (1)
  • April 2021 (2)
  • March 2021 (1)
  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • April 2019 (1)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 215-1313

Quick Links

  • Home
  • Physicians
  • About CureMatch
  • News and Latest Posts
  • Contact Us
  • FAQ

Latest News and Results

  • Launch of CureMatch Certified Precision Oncology Recognition Award May 8

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment Oct 7

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments Jun 28

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

© 2025 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

Please fill out the information below and a CureMatch representative will reach out to you.

 

Physician Request

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data